$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[해외논문] Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson’s Disease 원문보기

Current biology : CB, v.30 no.2, 2020년, pp.276 - 291.e9  

Heo, Jun Young (Center for Neuroscience, Korea Institute of Science and Technology (KIST)) ,  Nam, Min-Ho (Center for Neuroscience, Korea Institute of Science and Technology (KIST)) ,  Yoon, Hyung Ho (Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine) ,  Kim, Jeongyeon (Center for Neuroscience, Korea Institute of Science and Technology (KIST)) ,  Hwang, Yu Jin (Center for Neuro-Medicine, Brain Science Institute, KIST) ,  Won, Woojin (Center for Neuroscience, Korea Institute of Science and Technology (KIST)) ,  Woo, Dong Ho (Center for Neuroscience, Korea Institute of Science and Technology (KIST)) ,  Lee, Ji Ae (Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine) ,  Park, Hyun-Jung (Department of Science in Korean Medicine, Graduate School, Kyung Hee University) ,  Jo, Seonmi (Center for Neuroscience, Korea Institute of Science and Technol) ,  Lee, Min Joung ,  Kim, Sunpil ,  Shim, Jeong-Eun ,  Jang, Dong-Pyo ,  Kim, Kyoung I. ,  Huh, Sue H. ,  Jeong, Jae Y. ,  Kowall, Neil W. ,  Lee, Junghee ,  Im, Hyeonjoo ,  Park, Jong Hyun ,  Jang, Bo Ko ,  Park, Ki Duk ,  Lee, Hyunjoo J. ,  Shin, Hyogeun ,  Cho, Il-Joo ,  Hwang, Eun Mi ,  Kim, YoungSoo ,  Kim, Hye Yun ,  Oh, Soo-Jin ,  Lee, Seung Eun ,  Paek, Sun Ha ,  Yoon, Jong Hyuk ,  Jin, Byung K. ,  Kweon, Gi Ryang ,  Shim, Insop ,  Hwang, Onyou ,  Ryu, Hoon ,  Jeon, Sang Ryong ,  Lee, C. Justin

Abstract AI-Helper 아이콘AI-Helper

Summary Current pharmacological treatments for Parkinson’s disease (PD) are focused on symptomatic relief, but not on disease modification, based on the strong belief that PD is caused by irreversible dopaminergic neuronal death. Thus, the concept of the presence of dormant dopaminergic neuro...

Keyword

참고문헌 (69)

  1. Cold Spring Harb. Perspect. Med. Dickson 2 2012 10.1101/cshperspect.a009258 Parkinson’s disease and parkinsonism: neuropathology 

  2. Neurology Armon 47 626 1996 10.1212/WNL.47.3.626 Reversible parkinsonism and cognitive impairment with chronic valproate use 

  3. Neurol. Sci. Santos 36 1031 2015 10.1007/s10072-015-2126-0 Reversible parkinsonism and cognitive deficits due to vitamin B12 deficiency 

  4. Intern. Med. Okada 44 739 2005 10.2169/internalmedicine.44.739 Amelioration of extrapontine myelinolysis and reversible parkinsonism in a patient with asymptomatic hypopituitarism 

  5. Mov. Disord. Guan 27 156 2012 10.1002/mds.23935 Reversible parkinsonism due to involvement of substantia nigra in Epstein-Barr virus encephalitis 

  6. Proc. Natl. Acad. Sci. USA Joh 75 4744 1978 10.1073/pnas.75.10.4744 Direct phosphorylation of brain tyrosine hydroxylase by cyclic AMP-dependent protein kinase: mechanism of enzyme activation 

  7. J. Biol. Chem. Kilbourne 267 7563 1992 10.1016/S0021-9258(18)42553-7 Regulated expression of the tyrosine hydroxylase gene by membrane depolarization. Identification of the responsive element and possible second messengers 

  8. J. Neurochem. Aumann 116 646 2011 10.1111/j.1471-4159.2010.07151.x Neuronal activity regulates expression of tyrosine hydroxylase in adult mouse substantia nigra pars compacta neurons 

  9. Exp. Neurobiol. Qi 26 97 2017 10.5607/en.2017.26.2.97 Optogenetic rescue of locomotor dysfunction and dopaminergic degeneration caused by alpha-synuclein and EKO genes 

  10. Neurology Saari 88 1461 2017 10.1212/WNL.0000000000003810 Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease 

  11. J. Neurochem. Chen 105 78 2008 10.1111/j.1471-4159.2007.05108.x VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease 

  12. Front. Aging Neurosci. Bellucci 9 330 2017 10.3389/fnagi.2017.00330 The end is the beginning: Parkinson’s disease in the light of brain imaging 

  13. Mov. Disord. McGeer 23 474 2008 10.1002/mds.21751 Glial reactions in Parkinson’s disease 

  14. Nat. Med. Liberatore 5 1403 1999 10.1038/70978 Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease 

  15. Neurobiol. Dis. L’Episcopo 41 508 2011 10.1016/j.nbd.2010.10.023 Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease 

  16. Ann. N Y Acad. Sci. Hirsch 991 214 2003 10.1111/j.1749-6632.2003.tb07478.x The role of glial reaction and inflammation in Parkinson’s disease 

  17. Exp. Neurobiol. Joe 27 77 2018 10.5607/en.2018.27.2.77 Astrocytes, microglia, and Parkinson’s disease 

  18. J. Neurosci. Hennessy 35 8411 2015 10.1523/JNEUROSCI.2745-14.2015 Astrocytes are primed by chronic neurodegeneration to produce exaggerated chemokine and cell infiltration responses to acute stimulation with the cytokines IL-1β and TNF-α 

  19. J. Neurosci. Tao 31 8306 2011 10.1523/JNEUROSCI.0567-11.2011 Deletion of astroglial Dicer causes non-cell-autonomous neuronal dysfunction and degeneration 

  20. Nat. Neurosci. Di Giorgio 10 608 2007 10.1038/nn1885 Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model 

  21. Proc. Natl. Acad. Sci. USA Bi 110 4069 2013 10.1073/pnas.1218497110 Reactive astrocytes secrete lcn2 to promote neuron death 

  22. J. Biol. Chem. Lee 285 9262 2010 10.1074/jbc.M109.081125 Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies 

  23. Glia Fellner 61 349 2013 10.1002/glia.22437 Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia 

  24. Sci. Rep. Sun 8 383 2018 10.1038/s41598-017-18786-w Lack of PINK1 alters glia innate immune responses and enhances inflammation-induced, nitric oxide-mediated neuron death 

  25. FASEB J. Waak 23 2478 2009 10.1096/fj.08-125153 Regulation of astrocyte inflammatory responses by the Parkinson’s disease-associated gene DJ-1 

  26. Sci. Rep. Filichia 6 32656 2016 10.1038/srep32656 Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson’s disease model induced by MPTP 

  27. Nat. Med. Jo 20 886 2014 10.1038/nm.3639 GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease 

  28. Nat. Commun. Wu 5 4159 2014 10.1038/ncomms5159 Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer’s [corrected] disease model 

  29. Exp. Neurobiol. Oh 26 113 2017 10.5607/en.2017.26.3.113 Distribution and function of the bestrophin-1 (Best1) channel in the brain 

  30. Exp. Neurobiol. Chun 27 155 2018 10.5607/en.2018.27.3.155 Astrocytic proBDNF and tonic GABA distinguish active versus reactive astrocytes in hippocampus 

  31. J. Neurol. Cereda 264 1254 2017 Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study 

  32. Nature Zhang 446 633 2007 10.1038/nature05744 Multimodal fast optical interrogation of neural circuitry 

  33. J. Neurosci. Sato 31 16884 2011 10.1523/JNEUROSCI.3967-11.2011 Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson’s disease 

  34. Gene Niwa 108 193 1991 10.1016/0378-1119(91)90434-D Efficient selection for high-expression transfectants with a novel eukaryotic vector 

  35. Prog. Neurobiol. Schwarting 50 275 1996 10.1016/S0301-0082(96)00040-8 The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments 

  36. Nat. Neurosci. Boyden 8 1263 2005 10.1038/nn1525 Millisecond-timescale, genetically targeted optical control of neural activity 

  37. Nat. Protoc. Jackson-Lewis 2 141 2007 10.1038/nprot.2006.342 Protocol for the MPTP mouse model of Parkinson’s disease 

  38. Nat. Genet. Grimsby 17 206 1997 10.1038/ng1097-206 Increased stress response and beta-phenylethylamine in MAOB-deficient mice 

  39. Sci. Adv. Park 5 v0316 2019 10.1126/sciadv.aav0316 Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease 

  40. Lab Chip Lee 15 1590 2015 10.1039/C4LC01321B A multichannel neural probe with embedded microfluidic channels for simultaneous in vivo neural recording and drug delivery 

  41. Nat. Neurosci. Schiemann 15 1272 2012 10.1038/nn.3185 K-ATP channels in dopamine substantia nigra neurons control bursting and novelty-induced exploration 

  42. J. Neurosci. Grace 4 2866 1984 10.1523/JNEUROSCI.04-11-02866.1984 The control of firing pattern in nigral dopamine neurons: single spike firing 

  43. Science Lee 330 790 2010 10.1126/science.1184334 Channel-mediated tonic GABA release from glia 

  44. J. Physiol. Yoon 592 4951 2014 10.1113/jphysiol.2014.278754 Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition 

  45. Proc. Natl. Acad. Sci. USA Levitt 79 6385 1982 10.1073/pnas.79.20.6385 Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons 

  46. Adv. Neurol. Riederer 45 111 1987 Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl 

  47. Proc. Natl. Acad. Sci. USA Caraiscos 101 3662 2004 10.1073/pnas.0307231101 Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors 

  48. Brain Res. Bull. Park 89 92 2012 10.1016/j.brainresbull.2012.07.001 Transient receptor potential vanilloid subtype 1 contributes to mesencephalic dopaminergic neuronal survival by inhibiting microglia-originated oxidative stress 

  49. Proc. Natl. Acad. Sci. USA Woo 115 5004 2018 10.1073/pnas.1721187115 Control of motor coordination by astrocytic tonic GABA release through modulation of excitation/inhibition balance in cerebellum 

  50. Cell Woo 151 25 2012 10.1016/j.cell.2012.09.005 TREK-1 and Best1 channels mediate fast and slow glutamate release in astrocytes upon GPCR activation 

  51. Behav. Brain Res. Iancu 162 1 2005 10.1016/j.bbr.2005.02.023 Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice 

  52. Neurosurgery Yoon 74 533 2014 10.1227/NEU.0000000000000297 Optogenetic inactivation of the subthalamic nucleus improves forelimb akinesia in a rat model of Parkinson disease 

  53. Brain Res. Kim 1306 176 2010 10.1016/j.brainres.2009.09.103 Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson’s disease 

  54. Annu. Rev. Neurosci. Shih 22 197 1999 10.1146/annurev.neuro.22.1.197 Monoamine oxidase: from genes to behavior 

  55. Brain Res. Bull. Sundström 21 257 1988 10.1016/0361-9230(88)90240-7 Time course of MPTP-induced degeneration of the nigrostriatal dopamine system in C57 BL/6 mice 

  56. J. Neurochem. Fornai 73 2434 1999 10.1046/j.1471-4159.1999.0732434.x Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study 

  57. Lancet Neurol. Dickson 8 1150 2009 10.1016/S1474-4422(09)70238-8 Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria 

  58. N. Engl. J. Med. Olanow 361 1268 2009 10.1056/NEJMoa0809335 A double-blind, delayed-start trial of rasagiline in Parkinson’s disease 

  59. Neurology Pålhagen 66 1200 2006 10.1212/01.wnl.0000204007.46190.54 Selegiline slows the progression of the symptoms of Parkinson disease 

  60. Br. J. Clin. Pharmacol. Binde 84 1917 2018 10.1111/bcp.13651 A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson’s disease 

  61. Curr. Pharm. Des. Edmondson 20 155 2014 10.2174/13816128113190990406 Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: biological implications 

  62. PLoS ONE Mallajosyula 3 e1616 2008 10.1371/journal.pone.0001616 MAO-B elevation in mouse brain astrocytes results in Parkinson’s pathology 

  63. Nature Liddelow 541 481 2017 10.1038/nature21029 Neurotoxic reactive astrocytes are induced by activated microglia 

  64. Stereotact. Funct. Neurosurg. Yoon 94 41 2016 10.1159/000442891 Optogenetic inhibition of the subthalamic nucleus reduces levodopa-induced dyskinesias in a rat model of Parkinson’s disease 

  65. Paxinos 1998 The Rat Brain in Stereotaxic Coordinates 

  66. Br. J. Pharmacol. Son 165 2213 2012 10.1111/j.1476-5381.2011.01692.x A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson’s disease induced by MPTP 

  67. Sci. Rep. Lee 7 46675 2017 10.1038/srep46675 WINCS Harmoni: closed-loop dynamic neurochemical control of therapeutic interventions 

  68. Anal. Chem. Oh 88 10962 2016 10.1021/acs.analchem.6b02605 Monitoring in vivo changes in tonic extracellular dopamine level by charge-balancing multiple waveform fast-scan cyclic voltammetry 

  69. Neurotox. Res. Simola 11 151 2007 10.1007/BF03033565 The 6-hydroxydopamine model of Parkinson’s disease 

LOADING...

활용도 분석정보

상세보기
다운로드
내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

관련 콘텐츠

오픈액세스(OA) 유형

BRONZE

출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문

유발과제정보 저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로